

Press release from Emotra AB (publ)

Göteborg, July 3, 2017

Communiqué from the Annual General Meeting of EMOTRA AB (publ)

The Annual General Meeting of EMOTRA AB (publ) was held on Friday, June 30, 2017. The resolutions, summarised below, were adopted with the necessary majority.

Net income appropriation

The AGM approved the Board's proposal for allocation of the Company's loss as presented in the annual report. Furthermore, the Board recommends no dividend be paid for the financial year 2016. The AGM also granted the Board of Directors and the CEO discharge for the financial year 2016.

Determination of the number of board members and deputy members, as well as the number of accountants and deputy accountants; determination of the fees to be paid to the board members and accountant

The AGM decided that the Board shall be composed of four regular members and no deputy members and set the annual compensation for the chairperson to 80,000 SEK and 40,000 SEK each for regular members who are not employed by the Company. Furthermore, the AGM decided that an auditor and a deputy auditor shall be appointed, and that they shall be compensated in line with usual charges and upon presentation of approved invoice.

Election of Board of Directors and accountant

The AGM decided that Margit Ferm, Claes Holmberg, Roy Jonebrant and Lars-Håkan Thorell shall be reelected as regular board members. Furthermore, the AGM passed a resolution to renew the appointment of Thomas Nilsson as the Company's auditor and Marcus Hellsten as deputy auditor until next year's Annual General Meeting.

Resolution on amendment of the Articles of Association

The AGM approved the following changes in the Company's articles of association:

<i>Present phrasing</i>	<i>Approved phrasing</i>
§ 4 Share capital The share capital shall amount to a minimum of SEK 960,438.60 and a maximum of SEK 3,841,754.40.	§ 4 Share capital The share capital shall amount to a minimum of SEK 1,760,804.10 and a maximum of SEK 7,043,216.40.
§ 5 Number of shares The number of outstanding shares shall be at least 5,191,560 and at most 20,766,240.	§ 5 Number of shares The number of outstanding shares shall be at least 9,517,860 and at most 38,071,440.
§ 6 Board of Directors The Board of Directors shall consist of a minimum of three and a maximum of six members and not more than two deputy members.	§ 6 Board of Directors The Board of Directors shall consist of a minimum of four and a maximum of six members and not more than two deputy members.
§ 12 Reconciliation reservation Shares in the Company shall be registered in a share register in accordance with the Swedish Financial Instruments Accounts Act (1998:1479).	§ 12 Reconciliation reservation Shares in the Company shall be registered in a share register in accordance with the Swedish Financial Instruments Accounts Act (1998:1479) (Reconciliation reservation).

Sävedalen, June 2017

Emotra AB (publ)

THE BOARD OF DIRECTORS

For further information about Emotra, please contact:

Claes Holmberg, CEO
 Telephone: +46 708 25 45 47
 E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden
Tel: +46 708 25 45 47, www.emotra.se